Skip to main content

enobosarm

enobosarm: 2 clinical trials tracked.

enobosarm evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about enobosarm, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Obesity
Clinical Trial Registry Records (2)

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

NCT07446998Registry updated 2026-09-04·Phase 2·VERU
Active, not recruiting

Primary endpoint: To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.

InterventionalRandomizedtriple239 enrolledStarted 2026-03Completion 2027-1213 sites · United StatesVeru Inc.

A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management

NCT06282458Registry updated 2025-09-17·Phase 2·VERU
Completed

Primary endpoint: The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.

InterventionalRandomizedtriple168 enrolledStarted 2024-04Completion 2025-0814 sites · United StatesVeru Inc.